Clinical Research
Safety of tirofiban in patients with acute anterior circulation large vessel occlusive cerebral infarction during bridging endovascular treatment after intravenous thrombolysis
Chen Zhengwen, Li Peicheng, Liu Yizhi, Li Bo, Yuan Chen, Hou Kaiwen, Chen Long
Published 2023-02-15
Cite as Chin J Neuromed, 2023, 22(2): 149-156. DOI: 10.3760/cma.j.cn115354-20221111-00826
Abstract
ObjectiveTo investigate the safety of tirofiban in patients with anterior circulation acute large vessel occlusion cerebral infarction during bridging endovascular treatment (EVT) after intravenous thrombolysis (IVT).
MethodsTwo hundred and three patients received bridging EVT after IVT in Department of Intervention, First Affiliated Hospital of Soochow University from January 2017 to January 2022 were chosen. Patients were divided into tirofiban group (n=80) and non-tirofiban group (n=123) according to whether or not tirofiban was used during EVT, and then patients from tirofiban group were subdivided into stent implantation group (n=52) and non-stent implantation group (n=28) according to whether or not emergency stent implantation was performed. The clinical data, safety indexes (intracranial hemorrhage [ICH] rate 24 h, 2-3 d, and 90 d after EVT, new ICH incidence 3-90 d after EVT, fatal ICH rate, and mortality 90 d after EVT), and prognoses 90 d after EVT were compared.
Results(1) Compared with the non-tirofiban group, the tirofiban group had significantly higher proportions of males, and patients with tandem occlusion, balloon dilation or stent implantation, and statistically lower proportion of patients with atrial fibrillation, significantly longer surgical time, and significantly different distribution of stroke types (P<0.05). No significant differences were noted in ICH incidences 24 h after EVT, 2-3 d after EVT and 90 d after EVT, fatal ICH incidence, mortality incidence 90 d after EVT, or good prognosis rate 90 d after surgery between tirofiban group and non-tirofiban group (P>0.05). (2) Patients in the stent implantation group had significantly higher percentages of tandem occlusion and balloon dilation compared with those in the non-stent implantation group (P<0.05). No significant difference was noted in good prognosis rate 90 d after EVT or new ICH incidence 3-90 d after EVT between the stent implantation group and the non-stent implantation group (P>0.05). Compared with the non-stent implantation group, the stent implantation group had statistically higher ICH incidences 24 h after EVT, 2-3 d after EVT, and 90 d after EVT, significantly higher fatal ICH incidence and mortality 90 d after EVT (P<0.05).
ConclusionTirofiban is safe in patients with anterior circulation acute large vessel occlusion cerebral infarction during EVT after IVT; however, if emergency stent implantation is performed, it will lead to increased intracranial hemorrhage and mortality.
Key words:
Intravenous thrombolysis; Endovascular treatment; Tirofiban; Acute cerebral infarction
Contributor Information
Chen Zhengwen
Department of Intervention, First Affiliated Hospital of Soochow University, Suzhou 215006, China
Li Peicheng
Department of Intervention, First Affiliated Hospital of Soochow University, Suzhou 215006, China
Liu Yizhi
Department of Intervention, First Affiliated Hospital of Soochow University, Suzhou 215006, China
Li Bo
Department of Intervention, First Affiliated Hospital of Soochow University, Suzhou 215006, China
Yuan Chen
Department of Intervention, First Affiliated Hospital of Soochow University, Suzhou 215006, China
Hou Kaiwen
Department of Intervention, First Affiliated Hospital of Soochow University, Suzhou 215006, China
Chen Long
Department of Intervention, First Affiliated Hospital of Soochow University, Suzhou 215006, China
